Table 1.

Immunohistochemical analysis of HEY ovarian carcinoma xenograft after treatment with ZD4054 and paclitaxel

TreatmentTumor volume (cm3), mean ± SDMice tumor free (n)Median vessel density*Proliferation index Ki-67
Control3.7 ± 1.290/1067 ± 637.3 ± 1.5
ZD40541.78 ± 0.790/1025 ± 222.4 ± 3.3
Paclitaxel1.06 ± 0.820/1031 ± 227.7 ± 2.2
ZD4054 + Paclitaxel0.46 ± 0.1§4/1017 ± 2§15.7 ± 3.3§
  • NOTE: Nude mice were given a s.c. injection of 1.5 × 106 viable HEY cells on day 0. Treatment was started on day 7 after tumor injection. Mice were treated for 21 d i.p. with ZD4054 (10 mg/kg/day) or with paclitaxel (20 mg/kg i.v. every 4 d for three doses) or with a combination of ZD4054 + paclitaxel. Mice were sacrificed on day 40 after tumor injection, and immunohistochemical analysis was performed. Each group consisted of 10 mice. No histological evidence of HEY tumor was detected in 4 of 10 mice treated with the combination of paclitaxel and ZD4054.

  • * Vessel counts were assessed by light microscopy after staining for CD31. Areas containing the highest numbers of capillaries and small venules were identified by scanning at low power, and individual vessel counts were performed at ×200.

  • The relative number of proliferating cells was quantitatively assessed in 10 randomly selected fields (×200).

  • P < 0.05 compared with control.

  • § P < 0.002 compared with single treatments.